The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

Sean P. Dineen, Laura A. Sullivan, Adam W. Beck, Andrew F. Miller, Juliet G. Carbon, Roni Mamluk, Henry Wong, Rolf A. Brekken

Research output: Contribution to journalArticlepeer-review

57 Scopus citations

Fingerprint

Dive into the research topics of 'The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences